Advance of genetically modified pigs in xeno-transplantation

Jiacheng Deng, Lin Yang, Ziru Wang, Hongsheng Ouyang, Hao Yu, Hongming Yuan, Daxin PangFrontiers in Cell and Developmental Biology 2022 · DOI

Organ transplantation is a critical intervention for end-stage organ failure, yet a severe global shortage of human donors persists. Xenotransplantation—the transplantation of organs across species—offers a potential solution, with pigs emerging as the ideal candidates due to their physiological similarities to humans and rapid breeding cycles. However, significant immunological and biological barriers, including hyperacute rejection and viral risks, have historically hindered progress. Recent breakthroughs in genetic engineering, particularly CRISPR/Cas9 and base editing, are now overcoming these obstacles by creating "humanized" porcine donors.

Abstract

As the standard of living improves, chronic diseases and end-stage organ failure have been a regular occurrence in human beings. Organ transplantation has become one of the hopes in the fight against chronic diseases and end-stage organ failure. However, organs available for transplantation are far from sufficient to meet the demand, leading to a major organ shortage crisis. To solve this problem, researchers have turned to pigs as their target since pigs have many advantages as xenograft donors. Pigs are considered the ideal organ donor for human xenotransplantation, but direct transplantation of porcine organs to humans faces many obstacles, such as hyperacute rejection, acute humoral xenograft rejection, coagulation dysregulation, inflammatory response, and endogenous porcine retroviral infection. Many transgenic strategies have been developed to overcome these obstacles. This review provides an overview of current advances in genetically modified pigs for xenotransplantation. Future genetic engineering-based delivery of safe and effective organs and tissues for xenotransplantation remains our goal.

The Biological Hurdles of Xenotransplantation

The human immune system is evolutionarily primed to destroy porcine tissue through several mechanisms:

  1. Hyperacute Rejection (HAR): Immediate destruction of the graft by pre-existing antibodies.
  2. Acute Humoral Xenograft Rejection (AHXR): A slower, antibody-mediated attack.
  3. Coagulation Dysregulation: Incompatibilities between pig and human blood proteins leading to lethal blood clots (thrombotic microangiopathy).
  4. Biosafety: The risk of Porcine Endogenous Retroviruses (PERVs) jumping to human recipients.

Genetic Engineering Strategies

The field has transitioned from early transgenic methods to modern precision tools:

  • CRISPR/Cas9: Used to create "Triple Knockout" (TKO) pigs by deleting three major carbohydrate antigens ($\alpha$-Gal, Neu5Gc, and $Sd^a$) that trigger the human immune response.
  • Base Editing (CBE/ABE): A newer, "cleaner" method to create precise point mutations without causing double-stranded DNA breaks, reducing the risk of unintended genomic instability.
  • Multi-gene Stacking: Researchers are now developing "10G-pigs" (ten-gene modifications), combining multiple knockouts with the insertion of human complement regulatory proteins (e.g., hCD46, hCD55), anticoagulants (hTBM), and anti-inflammatory genes (hA20).

Key Insights and Humanization

  • The TKO Baseline: Deleting the three main sugar antigens is the "minimum viable product" for preventing immediate rejection, but long-term survival requires more.
  • Humanizing the Interface: Expressing human Thrombomodulin (hTBM) is critical to prevent the recipient's blood from clotting inside the pig organ.
  • The CD47 "Don't Eat Me" Signal: Expressing human CD47 on pig cells prevents human macrophages from attacking the graft.
  • The PERV Paradox: While CRISPR can inactivate all PERV sequences, the actual clinical risk remains debated, though inactivation is a necessary regulatory precaution.

Current Progress by Organ Type

Heart

Survival in non-human primates (NHP) has reached 945 days. A landmark 2022 case involved a human patient surviving 8 weeks with a 10G-pig heart, demonstrating that hyperacute rejection has effectively been defeated.

The evolution of cardiac xenotransplantation (CXTx) technology from early clinical trials to recent life-saving transplants.

Kidney

Pig-to-NHP survival now exceeds one year. Recent "bridge" studies in brain-dead human decedents showed immediate function (urine production) without rejection for the duration of the 74-hour study.

Liver

Liver xenotransplantation remains the most challenging due to severe thrombocytopenia (rapid drop in platelet count) in the recipient. Survival in NHPs is currently limited to approximately 29 days.

The evolution of liver xenotransplantation (LXT) technology, highlighting the persistent challenges in achieving long-term survival compared to other organs.

Limitations and Future Directions

Despite recent successes, several challenges remain:

  • Liver Incompatibility: The mechanism behind why pig livers destroy human platelets is not fully understood, though knocking out the ASGR1 receptor shows promise.
  • Chronic Rejection: Long-term outcomes (5–10 years) in humans remain unknown.
  • Ethical and Regulatory Hurdles: Transitioning to formal clinical trials requires standardized genetic "recipes" for donor pigs.
  • Monitoring: Developing non-invasive ways to monitor for porcine viruses in human recipients is a high priority for long-term safety.

Summary updated

Abstract

As the standard of living improves, chronic diseases and end-stage organ failure have been a regular occurrence in human beings. Organ transplantation has become one of the hopes in the fight against chronic diseases and end-stage organ failure. However, organs available for transplantation are far from sufficient to meet the demand, leading to a major organ shortage crisis. To solve this problem, researchers have turned to pigs as their target since pigs have many advantages as xenograft donors. Pigs are considered the ideal organ donor for human xenotransplantation, but direct transplantation of porcine organs to humans faces many obstacles, such as hyperacute rejection, acute humoral xenograft rejection, coagulation dysregulation, inflammatory response, coagulation dysregulation, and endogenous porcine retroviral infection. Many transgenic strategies have been developed to overcome these obstacles. This review provides an overview of current advances in genetically modified pigs for xenotransplantation. Future genetic engineering-based delivery of safe and effective organs and tissues for xenotransplantation remains our goal.
BibTeX
@inproceedings{deng2022advance,
  author = {Jiacheng Deng and Lin Yang and Ziru Wang and Hongsheng Ouyang and Hao Yu and Hongming Yuan and Daxin Pang},
  title = {{Advance of genetically modified pigs in xeno-transplantation}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2022},
  doi = {10.3389/fcell.2022.1033197},
}
Figure